^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

Excerpt:
After detection of the CUX1-ALK fusion gene...the patient showed a superior response to crizotinib, with a progression-free survival of 20 months....This study provides the novel finding of a CUX1-ALK fusion gene from a patient with NSCLC that could provide personalized treatment solutions for the maximum benefit to patients with NSCLC.
DOI:
10.1080/15384047.2018.1480282